Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.At one year, over half of patients with chronic kidney disease and type 2 diabetes continued sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment. Treatment options for these conditions were diverse across international patient cohorts.
Area Of Science
- Nephrology
- Endocrinology
- Pharmacology
Background
- The management of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is evolving.
- The FOUNTAIN platform (NCT05526157; EUPAS48148) analyzed CKD and T2D patient cohorts initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) prior to finerenone's market launch.
- This study focused on adult patients in Europe, Japan, and the US.
Purpose Of The Study
- To describe and compare patient cohorts with CKD and T2D initiating SGLT2i therapy.
- To analyze baseline characteristics and drug utilization patterns.
- To assess SGLT2i treatment persistence at one year.
Main Methods
- A multinational, multi-cohort study utilized five data sources: Danish National Health Registers (DNHR), PHARMO Data Network, Valencia Health System Integrated Database (VID), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex), and Optum's Clinformatics® Data Mart Database (CDM).
- Eligible patients had CKD and initiated an SGLT2i between 2012 and 2021.
- Baseline demographics, lifestyle, clinical characteristics, and drug utilization were analyzed.
Main Results
- Final cohorts comprised over 89,000 patients across the five data sources.
- Most patients (41-70%) had early-stage CKD (stage 1 or 2); severe CKD (stage 4) was infrequent (1.6-6.7%).
- Median SGLT2i therapy duration varied by data source (7.5 to 17.0 months), with at least 50% of patients remaining on SGLT2i treatment at one year.
Conclusions
- At one-year follow-up, at least half of patients with CKD and T2D continued SGLT2i treatment.
- Treatment options for T2D and CKD in patients initiating SGLT2i were heterogeneous and dynamic.
- Findings highlight SGLT2i persistence and treatment variability in this patient population.
Keywords:
CKD Chronic kidney disease Danish National Health Registers (DNHR) Drug utilization FOUNTAIN Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) Optum’s de-identified Clinformatics® Data Mart Database (CDM) PHARMO Data Network SGLT2 inhibitor T2D Type 2 diabetes Valencia Health System Integrated Database (VID)
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Class I comprises GLUT1 to GLUT4 and GLUT14.
Class II has GLUT5, GLUT7,...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...